在肌缩侧面硬化症中使用抗意义寡核酸治疗
Gergo Erdi-Krausz1,2, Pamela J Shaw1,2
1Sheffield Institute for Translational Neuroscience, the University of Sheffield.
Current opinion in neurology
|August 20, 2025
概括
反感性寡核酸 (ASO) 疗法在治疗肌缩侧面硬化症 (ALS),特别是SOD1-ALS方面表现有前途. 目前正在进行的研究探讨其他遗传突变和零星ALS的ASO,可能会逆转神经退行.
科学领域:
- 神经科学
- 遗传学
- 药理学
背景情况:
- 肌缩侧面硬化 (ALS) 是一种致命的神经退行性疾病,治疗选择有限.
- 最近对抗SOD1-ALS的tofersen,一种反感性寡核酸 (ASO) 的批准标志着一个重要的进步.
研究的目的:
- 对各种形式的ALS的ASO疗法的现状和未来潜力进行审查.
- 突出基于ASO的治疗前临床和临床发展.
主要方法:
- 对最近的临床试验和临床前研究,涉及ALS的ASO疗法.
- 专注于针对遗传突变的ASO (例如SOD1,C9orf72) 和零星ALS中的异常拼接.
- 使用来自患者的细胞和动物模型来评估治疗疗效.
主要成果:
- 在SOD1-ALS中,ASO疗法已取得成功.
- 针对C9orf72-ALS的试验面临挑战,但新的临床前数据提供了希望.
- 在偶发性ALS和TDP-43病理中针对异常拼接存在有希望的临床前结果.
结论:
- 对于家族性ALS,尤其是SOD1-ALS,ASO疗法是一个有前途的策略.
- 在其他遗传ALS形式和零星ALS中进行ASO应用的进一步研究.
- 这些疗法旨在阻止疾病的进展,并可能逆转神经退行.
相关概念视频
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Interference
26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375


